

Ref: SPL/CORP-SEC/2025-26/BSE/61

Dated:13.08.2025

To,
Bombay Stock Exchange Ltd,
Phirojshah Jeejobhoy Towers,
25th Floor, Dalal Street,
Mumbai 400 001

Manager-Department of Corporate affairs

Sir,

Sub: Outcome of the Board Meeting with Scrip Code 524703.

Pursuant to Regulations 30 & 33 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, A Meeting of the Board of Directors of the Company duly convened on Wednesday, 13th August 2025 at 03:00 p.m. and Concluded at 5.45 p.m. discussed the following business:-

1. Approved Unaudited Standalone Financial Results of the Company for the quarter ended June 30, 2025 were approved and taken on record, a copy of which is enclosed, together with Limited review Report with unmodified opinion thereon, issued by the Statutory Auditor of the Company .

Further to inform you that Sandu Pharmaceuticals Limited doesn't have any Subsidiary Company so consolidation of Accounts are not required for Q ended June 2025.

2. Approved Directors Report, Management Discussion and Analysis Report, Corporate Governance Report, Secretarial Audit Report etc for the year ended 31st March 2025.
3. Approved closure of Register of Members and Share Transfer Books of the Company from Tuesday, 23rd September 2025 To Tuesday, 30th September 2025 both days inclusive. The record date for determining the members eligible to receive the aforesaid dividend will be Thursday,18th September 2025.
4. Took note of Statement of Utilizations and Deviations as per Regulation 32 of SEBI (LODR) Regulation 2015 for the Quarter ended 30th June 2025.
5. To Convene 40th Annual General Meeting of the Company to be held on Tuesday, the 30th September 2025 at 04:30 pm in video conferencing/other Audio Visual Means.
6. Recommended the proposal for obtaining the approval of the shareholders at the ensuing Annual General Meeting for the further continuation of the material related party transactions with M/s Sandu Brothers Private Limited.
7. Approved continuation of Shri. Vijay Kajarekar as Chief Financial Officer on attending the age of 70 years subject to approval of the Shareholder in the ensuing Annual General Meeting.



SANDU PHARMACEUTICALS LIMITED

CIN:L24233GA1985PLC001587

Regd. Office: Plot Nos. 25, 26, 29 & 30, Pilerne Industrial Estate, Marra, Saligao, Bardez, Goa 403511.

Tel: +91 832 2407474 / 6715000, E-mail: sandupharma@sandu.in, Website: www.sandu.in

Disclosure of information pursuant to Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 read with SEBI Circular No. SEBI/HO /CFD/PoDZ/CIR/P/0155 dated November 11, 2024:

Yours Faithfully,

FOR SANDU PHARMACEUTICALS LTD.

Pratika Mhambray
Company Secretary & Compliance Officer
ACS:36512



AN ISO 9001:2015 CERTIFIED ORGANISATION
Corporate Office: P. B. No. 17201, Sandu Nagar, D. K. Sandu Marg, Chembur, Mumbai – 400 071.
Tel.: +91 22 2528 4402 / 3306, E-mail: info@sandu.in



Disclosure of information pursuant to Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 read with SEBI Circular No. SEBI/HO /CFD/PoDZ/CIR/P/0155 dated November 11, 2024:

| Sr No | Particulars | Details |
|-------|--|---|
| 1. | Reason for change viz. appointment, resignation, removal, death or Otherwise Completion of their terms | Proposed continuation of Shri. Vijay Kajarekar as Chief Financial Officer on completion of 70 years of age subject to approval of the shareholder in the ensuing Annual General Meeting. |
| 2. | Date of appointment/ Cessation and terms of appointment; | NA |
| 3. | Brief Profile (in case of appointment); | <p>Shri. Vijay Kajarekar is having 30 years of experience in various capacities of Finance, Taxation & Loan Syndication.</p> <p>Shri. Vijay Kajarekar has also worked as:</p> <ol style="list-style-type: none"> 1. Manager Finance - Goa Institute of Management. 2. Manager Finance - A.W. Faber Castell (India) Pvt. Ltd. 3. Manager Accounts & Finance - Goa Resistors Pvt. Ltd. 4. Sr. Manager Commercial - Goa Institute Industries Pvt. Ltd. |
| 4. | Disclosure of relationships between directors. (in case of Appointment) | NA |

FOR SANDU PHARMACEUTICALS LTD.

Pratika Mhambray
Company Secretary & Compliance Officer
ACS:36512



SANDU PHARMACEUTICALS LIMITED

CIN:L24233GA1985PLC001587

Regd. Office: Plot Nos. 25, 26, 29 & 30, Pileme Industrial Estate, Marra, Saligao, Bardez, Goa 403511.

Tel: +91 832 2407474 / 6715000, E-mail: sandupharma@sandu.in, Website: www.sandu.in

SANDU PHARMACEUTICALS LIMITED

Standalone Statement of unaudited result for the Period ended 30th June 25


| | | (Rs in Lakhs) | | | |
|------|---|----------------------|-----------------------|----------------------|-----------------------|
| | Particulars | Qtr Ending June 2025 | Qtr Ending March 2025 | Qtr Ending June 2024 | Year Ended March 2025 |
| | | (Un Audited) | (Audited) | (Un Audited) | (Audited) |
| | INCOME | | | | |
| I | Revenue From Operations | 1,669.90 | 1,406.92 | 1,704.54 | 6,719.24 |
| II | Other Income | 1.77 | 6.94 | 4.49 | 16.75 |
| III | Total Income (I+II) | 1,671.67 | 1,413.85 | 1,709.03 | 6,735.99 |
| IV | EXPENSES | | | | |
| | Cost of materials consumed | 191.08 | 301.49 | 227.41 | 1,011.98 |
| | Purchases of Stock-in-Trade | 358.75 | 728.92 | 394.11 | 2,318.45 |
| | Changes in inventories of finished goods, Stock-in-Trade and work-in-progress | 333.47 | (452.56) | 308.49 | (120.24) |
| | Employee benefits expense | 266.36 | 282.74 | 232.82 | 1,092.03 |
| | Finance costs | 2.64 | 2.63 | 2.13 | 10.33 |
| | Depreciation and amortization expense | 17.76 | 14.81 | 15.88 | 67.06 |
| | Other expenses | 467.73 | 501.57 | 501.10 | 2,140.80 |
| | Total expenses (IV) | 1,637.80 | 1,379.61 | 1,681.93 | 6,520.41 |
| V | Profit/(loss) before exceptional items and tax (III-IV) | 33.87 | 34.24 | 27.10 | 215.58 |
| VI | Exceptional Items / Prior Period Adjustment | - | - | - | - |
| VII | PROFIT/(LOSS) BEFORE TAX (V-VI) | 33.87 | 34.24 | 27.10 | 215.58 |
| VIII | Tax expense: | | | | |
| | (1) Current tax | (9.69) | (7.41) | (7.56) | (58.86) |
| | (2) Deferred tax | (0.63) | 5.81 | (2.86) | (1.83) |
| | Short / (Excess) Tax Provision | (1.22) | - | - | - |
| IX | PROFIT (LOSS) FOR THE PERIOD FROM CONTINUING OPERATIONS (VII-VIII) | 22.33 | 32.64 | 16.69 | 154.89 |
| X | PROFIT & LOSS FOR THE PERIOD (IX) | 22.33 | 32.64 | 16.69 | 154.89 |
| XI | OTHER COMPREHENSIVE INCOME | | | | |
| | A (i) Items that will not be reclassified to profit or loss in Subsequent Periods : | | | | |
| | (a) Remeasurement gains/(losses) on post employment defined benefit plans | - | (12.66) | - | (12.66) |
| | (b) Fair value changes of investments | 19.63 | 21.35 | 21.12 | 82.95 |
| | (ii) Income tax relating to items that will not be reclassified to profit or loss | (9.31) | 1.15 | (2.35) | (5.71) |
| | TOTAL OTHER COMPREHENSIVE INCOME FOR THE PERIOD (NET OF TAX) | 10.33 | 9.84 | 18.77 | 64.58 |
| XII | TOTAL COMPREHENSIVE INCOME FOR THE PERIOD (NET OF TAX) | 32.66 | 42.48 | 35.46 | 219.47 |
| XIV | Paid up Equity Capital (Face Value of Rs. 10/- Per Share) | 966.10 | 966.10 | 966.10 | 966.10 |
| | EARNINGS PER EQUITY SHARE (For continuing Operations) | | | | |
| | (1) Basic | 0.23 | 0.34 | 0.17 | 1.60 |
| | (2) Diluted | 0.23 | 0.34 | 0.17 | 1.60 |

For Sandu Pharmaceuticals Ltd

Umesh Sandu
Managing Director
DIN :- 01132141

Place: Mumbai

Dated : 13th August 2025



AN ISO 9001:2015 CERTIFIED ORGANISATION

Corporate Office: P. B. No. 17201, Sandu Nagar, D. K. Sandu Marg, Chembur, Mumbai - 400 071.
Tel.: +91 22 2528 4402 / 3306, E-mail: info@sandu.in



Notes to Accounts:

1. The above results published in accordance with regulation 33 of the SEBI (Listing Obligation & Disclosures Requirements), 2015 .The Financials results are in accordance with the Indian Accounting Standards (IND AS) as prescribed under Section 133 of the Companies Act, 2013 read with Rule 3 of the Companies (Indian Accounting Standards) Rule, 2015 and Companies (Indian Accounting Standards) Amendment Rules, 2017.
2. The Management evaluates the performance of the company based on revenue and operating income in one segment i.e. "Ayurvedic Proprietary Medicines". Accordingly, as per IND AS-108. The company has only one business segment and hence segment information has not been separately disclosed.
3. The above results were reviewed and recommended by the Audit Committee and approved by the Board of Directors at the meeting held on 13/08/2025.
4. The Figures for the Year ended 31 st March, 2025 are the balancing figures between the audited figures in respect of the full financial year and the published year to date figures up to nine months ended 31/12/2024.
5. Figures for the previous periods have been reclassified/regrouped, whenever necessary.
6. Sandu Pharmaceuticals Limited doesn't have any Subsidiary Company so consolidation of Accounts are not required for Q ended June 2025.

For Sandu Pharmaceuticals Ltd



Umesh Sandu
Managing Director
DIN no: - 01132141

Date: - 13/08/2025



**INDEPENDENT AUDITOR'S LIMITED REVIEW REPORT ON THE UNAUDITED STANDALONE
FINANCIAL RESULTS FOR THE QUARTER ENDED ON 30th JUNE, 2025**


To,

**The Board of Directors,
Sandu Pharmaceuticals Limited,**
Plot No. 25, 26, 29 & 30,
Pilerne Industrial Estate, Marra,
Bardez, Goa-403511.

Dear Sirs,

1. We have reviewed the accompanying Statement of Unaudited Standalone Financial Results of **Sandu Pharmaceuticals Limited** ("the Company") for the quarter ended on 30th June, 2025, prepared by the Company pursuant to the requirements of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended.
2. This Statement is the responsibility of the Company's Management and has been approved by the Board of Directors, has been prepared in accordance with the recognition and measurement principles laid down in the Indian Accounting Standard 34 "Interim Financial Reporting" (Ind As 34), prescribed under section 133 of the Companies Act, 2013 read with the relevant rules issued thereunder and other accounting principles generally accepted in India. Our responsibility is to issue a report on these standalone financial statements based on our review.
3. We conducted our review in accordance with the Standard on Review Engagement (*SRE*) 2410, "Review of Interim Financial Information Performed by the Independent Auditor of the Entity" issued by the Institute of Chartered Accountants of India. This standard requires that we plan and perform the review to obtain moderate assurance as to whether the financial statements are free of material misstatement. A review is limited primarily to inquiries of company personnel and analytical procedures applied to financial data and thus provide less assurance than an audit. We have not performed an audit and accordingly, we do not express an audit opinion.
4. Based on our review conducted as above, nothing has come to our attention that causes us to believe that the accompanying statement of Unaudited Financial Results prepared in accordance with the applicable Indian Accounting Standards prescribed under Section 133 of the Companies Act, 2013, read with relevant rules issued there under and other recognised accounting practices and principles generally accepted in India, has not disclosed the information required to be disclosed in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended, including the manner in which it is to be disclosed, or that it contains any material misstatement.

For Dileep & Prithvi
Chartered Accountants
Firm Registration Number: 122290W



Himmat Mali
(Partner)
Membership Number: 183378
UDIN-25183378BMNAQW4149



Place: Mumbai
Date: 13th August, 2025